Ribosome-Binding Agents for LDL Receptor Regulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents fail to effectively treat low-density lipoprotein (LDL) cholesterol-related diseases by inadequately regulating LDL receptors, leading to increased risks of vascular diseases such as heart diseases and cerebral vascular disorders due to excessive cholesterol accumulation.
Innovation Solution
A pharmaceutical and food composition comprising a ribosome-binding agent, such as deoxynivalenol (DON) or anisomycin (ANS), which increases the expression of LDL receptors in intestinal epithelial cells, promoting the absorption of LDL and reducing blood LDL levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapeutic agents are used to treat LDL cholesterol-related diseases, then treatment is provided, but LDL receptor regulation is inadequate leading to excessive cholesterol accumulation
Solution Approach 1:
The patent changes the molecular target parameter from general cholesterol management to specific ribosome binding, which triggers downstream effects on LDL receptor expression. By targeting the ribosome with specific compounds, the system achieves more effective regulation of LDL receptor activity and cholesterol metabolism compared to conventional therapeutic agents.
2Reliability
If LDL receptor activity is increased to eliminate circulating cholesterol, then cholesterol balance is improved, but vascular diseases still occur due to thrombus formation
Solution Approach 1:
The patent introduces ribosome-binding compounds as intermediary agents that mediate between the therapeutic goal and the biological system. These compounds bind to ribosomes and indirectly regulate LDL receptor expression through cellular response mechanisms, providing a more comprehensive therapeutic effect that addresses both cholesterol elimination and vascular health.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ribosome-binding agent effectively prevents or treats LDL-related diseases by enhancing LDL receptor expression, thereby reducing LDL levels in the blood, addressing conditions like hyperlipidemia, hypertension, and stroke.
Implementation Method 1
the composition comprises a ribosome-binding agent
Implementation Method 2
the ribosome inactivation increases the expression level of the LDL receptor
Data Source
AI summary
The present invention relates to: a pharmaceutical composition for preventing or treating LDL cholesterol-related diseases, containing a ribosome-binding preparation; a food composition; and a method for preventing or treating LDL cholesterol-related diseases by using the composition. According to the present invention, the ribosome-binding preparation selectively increases the expression of an LDL receptor in intestinal epithelial cells so as to promote LDL absorption in blood and tissue, such that LDL level in the blood can be reduced, thereby being useful for preventing or treating various LDL cholesterol-related diseases including LDL hypercholesterolemia, hyperlipidemia, hypertension and apoplexy.